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1. Introduction 
Necrotizing enterocolitis (NEC) is among the most common and devastating diseases that 
primarily afflicts preterm infants in neonatal intensive care units (NICU) (1). Despite recent 
advances in neonatal care, the incidence of necrotizing enterocolitis and the associated 
morbidity and mortality have remained unchanged because of the improved survival for 
smaller, more premature infants (2). Both medical and surgical management play critical 
role in the treatment of NEC once it occurs, but prevention is likely to have the most 
dramatic impact on overall morbidity and mortality.  
2. Epidemiology 
The incidence of NEC varies among NICUs worldwide, but ranges 3% and 28% with an 
average of 7% in infants born weighing less than 1500 g (3). NEC occurs more commonly in 
the smallest and most immature infants, with the incidence increasing inversely to 
gestational age and birth weight among appropriately grown preterm infants. Although 
NEC is almost exclusively a disease of prematurity, 5 % to 10 % of cases occur in infants 
born greater than or equal to 37 weeks gestation (4). Most of the infants in whom NEC 
develops are previously fed and the disease usually occurs in the second week of life after 
the initiation of enteral feeding (5). 
The estimated rate of death related with NEC ranges between 20 and 30 %, with the highest 
rate among infants requiring surgery (6). Beyond the mortality and gastrointestinal 
morbidities, NEC is also the harbinger of neurologic deficits and developmental  
delay (7). 
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3. Pathophysiology 
NEC is a disease with a multifactorial etiology leading to the one common final pathway of 
necrosis and inflammation of the neonatal intestine (8). Although the pathophysiology of 
NEC is incompletely understood, epidemiologic studies have identified multiple factors that 
increase an infant’s risk for the development of NEC, although prematurity, enteral feeding, 
intestinal ischemia/asphyxia and bacterial colonization are thought to play central roles in 
disease pathogenesis (9). 
Prematurity is the most consistent and important risk factor for NEC. Anand et al. (10) 
proposed major altered components of the intestinal barrier of preterm neonates such as 
disruption of the integrity of epithelial tight junctions, impaired peristalsis and deficiencies 
in components of the mucous coat that may contribute to the onset of NEC (11-13). 
Enteral feeding is a significant risk factor for disease in preterm infants, because most cases 
of NEC occur after feedings have been introduced. Although the precise relationship 
between enteral feeding and NEC remain poorly understood, studies have identified the 
importance of breast milk as opposed to formula, osmolality, volume and rate of feeding as 
important factors (14, 15). Breast milk appears to reduce the incidence of NEC in human 
studies and controlled animal models (16, 17). 
Intestinal ischemia is another risk factor in the development of NEC. There is a delicate 
balance between vasodilatation and vasoconstriction in neonatal circulation, mediated 
formerly by nitric oxide and the latter by endothelin-1. The basal intestinal vascular 
resistance is decreased by the predominance of nitric oxide. Pathologic states cause 
endothelial dysfunction which leads to endothelin-1 activation and resultant 
vasoconstriction, intestinal ischemia, and cellular injury (18). 
GI tract of the preterm infants are susceptible to abnormal bacterial colonization because of 
the immature immunologic defenses (9). The intestinal flora that is normally populated 
plays an important role in maintaining the intestinal barrier, and also has the ability to 
dampen the inflammatory response. Colonization of the intestine with pathogenic 
microorganisms, depending on the exposition to a variety of nosocomial bacteria in the 
NICUs and immature immune systems, may serve as predisposing factors in development 
of NEC in preterm infants (19). 
4. Diagnosis and management 
The clinical syndrome associated with NEC is nonspecific. Infants with NEC may exhibit 
several gastrointestinal signs including abdominal distention, increased gastric residuals, 
occult or gross blood in the stool, and abdominal wall erythema or ecchymosis. In addition 
to GI-specific signs, NEC infants may exhibit systemic signs such as lethargy, apnea, 
bradycardia and temperature instability (19). 
The diagnosis of disease continues to be made with the use of pathognomonic 
radiographic findings. The most specific signs, which still are the only "signs" that allow 
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the diagnosis to be confirmed prior to surgical inspection of the intestine, are 
pneumatosis intestinalis in most cases, hepatic portal venous gas or pneumoperitoneum 
in a minority of cases. A diagnosis requires one of the specific radiographic findings or 
direct inspection of the intestine in the clinical context (5, 20). As soon as the diagnosis of 
NEC is suspected, initial management should include bowel rest, decompression, 
cultures of blood, urine and sputum, administration of broad-spectrum antibiotics, 
appropriate fluid resuscitation, serial abdominal examinations and radiographs. Surgical 
intervention for NEC is required in 30% to 50% of cases reported; therefore close 
observation with serial examinations and radiographs is essential. Surgical intervention 
involving primer peritoneal drainage or laparatomy with the resection of affected bowel 
are generally required in infants with intestinal perforation or deteriorating clinical 
condition (20). 
5. Preventative strategies for NEC 
Based on the epidemiologic studies and understanding of the pathophysiology there have 
been several approaches attempted to prevent NEC in animal and human studies. 
Reduction of NEC has been shown with breast milk feeding, antibiotic prophylaxis, steroids, 
IgA supplementation, probiotics, epidermal growth factor, polyunsaturated fatty acids, 
platelet activating factor (PAF) antagonists, PAF-acetylhydrolase, trefoil factor, leukocyte 
depletion, and oxygen radical scavengers in animal models. In human studies, there 
remains no standard effective alternative for NEC prevention, although breast milk feeding 
is the best option that neonatologists have to offer. Besides breast milk feeding, strategies 
with the most evidence supporting their effectiveness are careful feeding advancement and 
prophylactic probiotics supplementation in at-risk neonates (4, 5). 
6. Probiotic prophylaxis in NEC 
The intestine of the newborn is devoid of bacterial flora at birth but is rapidly colonized 
thereafter (9). Although the maternal flora constitutes the main source of intestinal 
colonization, gestational age, the mode of delivery, the neonatal diet and genetic factors also 
influence the colonization (21). 
Colonization by commensal bacteria is required for the normal development and 
maturation of the newborn intestine. Lactobacilli and Bifidobacteria that are the principal 
kinds of probiotics bacteria predominate in the normal gut flora of healthy, breastfed, term 
neonates (22). In contrast, the intestine of the preterm infant tends to be colonized by 
different microorganisms, predominantly coliforms, enterococci and bacteroides species 
(23). Even among VLBW infants receiving breast milk, Sakata et al. (24) found that the 
Bifidobacteria were undetectable in the intestinal flora during the first 1 to 2 weeks after 
birth and did not predominate until after the third week of life. Hoy et al. (25) and Millar et 
al. (26) observed a decline in the variety of species and shift to a predominance of 
Enterobacteriaceae before the onset of NEC.  
 
Probiotics 436 
Intestinal microbiological flora is an important factor in the host-defense mechanism against 
bacterial infections. The combination of an increase in potentially pathogenic 
microorganisms together with a decrease "in normal flora" found in preterm infants is one of 
the factors that render these infants at increased risk of developing NEC (23, 27). It has been 
suggested that the growth of pathogens might be prevented by inducing the colonization of 
the intestine non-pathogenic bacteria (probiotics) of species normally resident in the gut of 
preterm and term infants (28). 
The identification of probiotics bacterial species involved in gut homeostasis and potential 
therapeutic benefits of probiotics have led to interest in their use in the prevention of NEC 
(29, 30). Probiotics compete with other microbes for binding sites and substrates in the 
bowel, enhance the IgA mucosal response, improve the mucosal barrier, reduce mucosal 
permeability, stimulate intestinal mucosal lactase activity, increase anti-inflammatory 
cytokines, and produce a wide range of antimicrobial substances such as bacteriocins, 
microcins, reuterin, hydrogen peroxide and hydrogen ions (20, 28). 
Gastrointestinal mucosa is the primary interface between the external environment and the 
immune system. Whenever intestinal microflora reduces, antigen transport is increased 
indicating that the normal gut microflora maintains gut defenses (31). The non-pathogenic 
probiotic bacteria interact with the gut epithelial cells and the immune cells to start the 
immune signals. These bacteria must interact with M cells in the Peyer’s patches, with gut 
epithelial cells, and with associated immune cells. Probiotic bacteria have been shown to 
modulate immunoglobulin production. Secretory IgA plays an important role in mucosal 
immunity, contributing to the barrier against pathogenic bacteria and viruses. The increase 
in the number of IgA producing cells was the most remarkable property induced by 
probiotic organisms (32, 33). 
Probiotic supplementation has resulted in a reduction in the incidence of NEC-like intestinal 
lesions in several animal models. Caplan et al. (34) demonstrated that Bifidobacteria 
supplementation resulted in intestinal colonization and subsequent reduction in NEC-like 
lesions in a neonatal rat model of intestinal ischemia/reperfusion. Butel et al. (35) showed in 
a NEC model in quail, that supplementation with Bifidobacteria prevented the development 
of cecal lesions reminiscent of NEC. 
Several studies have specially assessed the colonization pattern and the incidence of NEC in 
preterm infants supplemented with various probiotics (19, 36-38). (Table 1)  
A randomized controlled trial found that infants whose feed was supplemented with 
Bifidobacterium breve had higher rates of fecal bifidobacterial colonization at 2 weeks of age 
(73 vs. 12 %), improved weight gain and had feeding tolerance. However, the incidence and 
severity of NEC were not reported in this study (39). 
In a multicenter double-blind study, preterm infants with a gestational age of <33 weeks or 
birth weight of <1500 g, who survived 42 weeks, were randomized to receive either placebo 
or L. rhamnosus GG (LB-GG) once a day, starting with the first fed until discharged. The 
incidence of urinary tract infection, bacterial sepsis and NEC were examined as outcome 
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measures. There were no significant differences between the probiotics and placebo groups 
with regard to any of the outcome variables (28). 
Another study performed by Bin-Nun et al. (40) was conducted to test the hypothesis that 
normalizing the intestinal flora by administration of prophylactic probiotics would provide 
a natural defense, thereby reducing both the incidence and severity of NEC in preterm 
infants. Preterm infants ≤1500g birth weight were randomized to either receive a daily 
feeding supplementation with a probiotic mixture (Bifidobacteria infantis, Bifidobacteria 
bifidus, and Streptococcus thermophilus) of 109 cfu/day or to not receive feed supplements. 
In this study, probiotic supplementation had resulted in a reduction in the incidence and the 
severity of NEC in very low birth weight (VLBW) infants. 
In addition, Lin et al. (19) reported a decrease in NEC, NEC plus mortality and severity of 
NEC, following probiotics L. acidophilus and B. infantis (Infloran), prophylaxis in a 
prospective, randomized blinded study. They also recently reported a multicenter-blinded 
trial regarding who were randomized to receive Bifidobacterium bifidum and L. acidophilus 
for 6 weeks. The results showed a significant reduction in the incidence of death or NEC and 
no adverse effect, such as sepsis, flatulence or diarrhea (37). 
Similarly, Hoyos (36) reported a significant reduction in the incidence of NEC and NEC-
associated death in infants in the NICU after the prophylactic administration of probiotics in 
the form of Infloran-supplemented enteral feeding. However, infants were more mature and 
generally had higher birth weights; it is not a blinded trial and comparison was made with 
historical controls.  
The results of the study performed by Sari et al (38) suggested a trend toward lower 
incidence of NEC and, death or NEC, although the difference was not statistically 
significant. None of the L. sporogenes-supplemented fed infants died from NEC; they could 
not find significant difference in severity of NEC or in mortality rate attributable to NEC 
between the probiotics and control groups. The use of a single probiotics agent rather than 
two agents and utility of a relatively low dose of L. sporogenes may explain, at least in part, 
the smaller treatment effect in their study. Longer duration of umbilical venous 
catheterization in probiotics group also may be another cause in the lesser effect of L. 
sporogenes on NEC prevention. 
In a recent report by Manzoni et al. (41) routinely supplementation of probiotic LB-GG in a 
large, 6-year VLBW infants cohort was proved microbiologically safe and clinically well 
tolerated. 
Although some of the studies (19) predicated that probiotics may reduce the incidence of 
sepsis; literature did not confirm this association (42, 43). Sari et al. (38) also did not show 
that L. sporogenes reduced the incidence of sepsis in VLBW infants. Sepsis has a complex 
pathogenesis that is favored by many factors (that is, immune deficiencies of preterm 
infants, type and frequency of invasive procedures and so on) that cannot be influenced by 
probiotic administration. The main effect of orally administered probiotics is in the 
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gastrointestinal tract, and so probiotics alone cannot overcome the invasive procedures 
including infection. 
Lactobacilli and Bifidobacteria are generally regarded as non-pathogenic, except a few 
reported cases of Lactobacillus bacteremia that seemed to occur in immunocompromised or 
extremely sick infants receiving high doses of Lactobacillus (44). Kunz et al. (45) described L. 
bacteremia in two preterm infants who received LB- GG, and both of those infants had 
short-gut syndrome. The other authors did not observe sepsis attributable to probiotics in 
the studies (28, 44, 45). Sari et al (38) observed no cases of sepsis or other adverse effects, 
such as diarrhea, flatulence attributable to probiotic supplementation. 
In 2011, Alfaleh et al. (29) performed a meta-analysis of randomized controlled trials, 
including some of those discussed here, to evaluate the efficacy of probiotics in the 
prevention of severe NEC and/or sepsis in preterm infants. Sixteen eligible trials 
randomizing 2842 infants were included. Included trials were highly variable with regard to 
enrollment criteria (i.e. birth weight and gestational age), baseline risk of NEC in the control 
groups, timing, dose, formulation of the probiotics, and feeding regimens. In a meta-
analysis of trial data, enteral probiotics supplementation significantly reduced the incidence 
of severe NEC (stage ≥2) (typical RR 0.35, 95% CI 0.24 to 0.52) and mortality (typical RR 0.40, 
95% CI 0.27 to 0.60). There was no evidence of significant reduction of nosocomial sepsis 
(typical RR 0.90, 95% CI 0.76 to 1.07). The included trials reported no systematic infection 
with probiotic supplemental organism. Author concluded that enteral supplementation of 
probiotics prevents severe NEC and all cause mortality in preterm infants. 
A recent systematic review performed by Mihatsch et al. (46) reported that there is 
insufficient evidence to recommend routine probiotics. However there is encouraging data 
which justifies the further investigation regarding the efficacy and safety of specific 
probiotics in circumstances of high local incidence of severe NEC. 
There is limited information about the long-term effects of probiotics supplementation in 
neonates. Chou et al. (47) reported the long-term neurodevelopmental outcomes of preterm 
infants in their trial of oral probiotics for NEC. A total of 83.1% of infants from their trial 
were assessed by Bayley infant developmental assessment tool (BSID-II) at 3 years’ 
corrected age; 1 of 153 and 4 of 148 had died after discharge. There were no significant 
differences in growth, neurodevelopmental and sensory outcomes at 3 years’ corrected age. 
Recently, a prospective follow-up study was conducted to evaluate growth and 
neurodevelopmental outcomes in a cohort of infants enrolled in a randomized controlled 
trial of oral probiotics for the prevention of NEC in VLBW infants. The authors concluded 
that administration of oral probiotics to VLBW infants in the early neonatal period had no 
adverse effects on growth, neuromotor, neurosensory, and cognitive outcomes at 18-22 
months' corrected age (48). Given the importance of this issue, it is critical that authors of 
all trials in this field report long-term neurodevelopmental outcomes of the enrolled 
infants.  
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Source GA/BW  
Probiotic
Agent(s) 
Dosage and 
Duration 
Type of 
milk 
Results 
Hoyos et al,  
(36) 1999  
<37 wk LB-A,BI 
LB-A 0.25x109 CFU, 
BI 0.25x109 CFU, once 
daily from first feed 
until discharge 
MM, DM, 
or FM 
Significant 
decrease in NEC 
and NEC 
associated 
mortality  
Dani et al,  
(28) 2002  
<33 wk or  
<1500 g 
LB-GG 
6x109 CFU once daily 
from first feed until 
discharge 
MM, DM, 
or FM 
Non-significant 
decrease in NEC, 
UTI and sepsis 
Bin-Nun et al, 
(40) 2005  
<1500 g BI, ST, BBB
BI 0.35x109 CFU, ST 
0.35x109 CFU, BBB 
0.35x109 CFU once 
daily from first feed 
to 36 wk corrected 
age 
MM or 
FM 
Significant 
decrease in NEC  
Lin et al,  
(19) 2005  
<1500 g LB-A, BI 
LB-A 1004356 and BI 
1015697 organisms 
twice daily from day 
7 until discharge 
MM or 
DM 
Significant 
decrease in NEC 
or death 
Lee et al,  
(49) 2007 
<37 wk LB-A 
108 CFU from first 
feed for 14 d  
MM or 
FM 
Non-significant 
decrease in NEC, 
improved 
feeding 
tolerance 
Lin et al,  
(37) 2008 
<34 wk and 
<1500 g 
LB-A, BBB 
2 x 109 CFU/d for 6 
wk  
MM or 
FM 
Significant 
decrease in NEC 
or death  
Samanta et al  
(50), 2009  
<34 wk and 
<1500 g 
BBB, BB-L,
BI, LB-A 
2.5x109 CFU/d until 
discharge 
MM or 
FM 
Significant 
decrease in NEC, 
death or sepsis  
Sari et al  
(38), 2011 
<33 wk or 
<1500 g 
LB-S 
0.35x109 CFU/d from 
first feed until 
discharge 
MM or 
FM 
Non-significant 
decrease in NEC 
or death, 
improved 
feeding 
tolerance  
Table 1. Studies examining effect of probiotic supplementation on incidence of NEC 
 
Probiotics 440 
GA indicates gestational age; BW, birth weight; LB-A, Lactobacillus acidophilus; 
BI,Bifidobacteria infantis; LB-GG, Lactobacillus GG; ST, Streptococcus thermophilus; BBB, 
Bifidobacterium bifidus; BB-L, Bifidobacteria longum; LB-S, Lactobacillus sporogenes; CFU, 
colony forming unit; MM, mother’s milk; DM, donor milk; FM, formula milk; UTI, urinary 
tract infection 
7. Summary 
NEC is one of the commonest causes of acute morbidity and mortality in preterm infants as 
well as a cause of long term disability for older children. The pathogenesis is multifactorial 
but probably requires the classic triad of injury to the intestinal mucosa, presence of enteral 
food substrate and the presence of bacteria and bacterial products. Recent advances in 
neonatology have led to improved survival for younger and smaller infants, and a resultant 
increase in the disease burden of NEC. The morbidity and mortality rates for NEC have still 
remained constant, by contrast with the improvement in outcomes for many prematurity-
related diseases. There are several prosperous researches that could ultimately result in 
novel preventative or therapeutic options but there is currently no effective preventive 
strategy, and treatment options are limited. 
Although probiotics may be a promising approach for prevention and decreased severity of 
NEC, issues exist regarding the standardization of an appropriate probiotic supplement for 
neonates. Most studies have utilized various combinations of probiotic bacteria and 
amounts of culture-forming units for different lengths of time. These differences in 
methodology have created difficulties in elucidating the most beneficial probiotic 
supplement for the preterm population. Questions remain concerning the strains or 
combinations of strains that offer the best benefit. Potential exists for a significant difference 
in the magnitude of the benefit when administered to formula versus breast-fed neonates. 
There are also uncertainties over the optimal time to start probiotics in order to confer 
maximal benefit, possible adverse effects including probiotic-associated sepsis and tolerance 
of milk feeding and the long-term consequences of probiotic supplementation. So, before 
routine probiotic prophylaxis could be recommended to neonatologists, it would be 
important to have evidence in support of such use from large, prospective, single-protocol, 
randomized, double-blind trials. 
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